Login to Your Account



Uniqure FIXes sights on quick drive to hemophilia B try

By Randy Osborne
Staff Writer

Thursday, October 19, 2017

"Nobody ever thought that you could make a modification to the transgene and not start over," Uniqure NV CEO Matt Kapusta told BioWorld, but that's what the company did with its gene therapy for hemophilia B, and Wall Street was delighted.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription